BiotechTube

4D-310

Phase 1/2Recruiting
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Fabry Disease

Conditions

Fabry Disease

Trial Timeline

Oct 16, 2022 → Jun 1, 2030

NCT ID
NCT05629559

About 4D-310

4D-310 is a phase 1/2 stage product being developed by 4D Molecular Therapeutics for Fabry Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05629559. Target conditions include Fabry Disease.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (2)

NCT IDPhaseStatus
NCT05629559Phase 1/2Recruiting
NCT04519749Phase 1/2Active

Competing Products

20 competing products in Fabry Disease

See all competitors
ProductCompanyStageHype Score
LucerastatIdorsiaPhase 3
72
Fabrazyme (agalsidase beta)SanofiPhase 2
51
Venglustat (GZ402671) + PlaceboSanofiPhase 3
76
Fabrazyme (agalsidase beta) + Fabrazyme (agalsidase beta)SanofiPhase 2
51
agalsidase betaSanofiApproved
84
TropicamideSanofiPre-clinical
22
Fabrazyme (agalsidase beta)SanofiApproved
84
agalsidase betaSanofiApproved
84
AGALSIDASE BETA (GZ419828) + Acetaminophen + Diphenhydramine + Dexamethasone + Montelukast + Loratadine + Cetirizine + FexofenadineSanofiApproved
84
Gabapentin + placeboSanofiPhase 2
51
Agalsidase betaSanofiApproved
84
GZ/SAR402671SanofiPhase 2
51
agalsidase beta (GZ419828) + agalsidase alfaSanofiApproved
84
Fabrazyme (agalsidase beta)SanofiPhase 3
76
Venglustat (GZ402671) + Agalsidase alfa + Agalsidase beta (GZ419828) + MigalastatSanofiPhase 3
76
IohexolSanofiPhase 1
32
GZ/SAR402671SanofiPhase 2
51
Fabrazyme (agalsidase beta)SanofiPhase 2
51
Agalsidase betaSanofiApproved
84
Fabrazyme (agalsidase beta) + PlaceboSanofiApproved
84

Other Products from 4D Molecular Therapeutics

4D-150 IVT (3E10 vg/eye) + EYLEA® (aflibercept) Injection 2 mg (0.05mL)Phase 3
69
4D-150 IVT (3E10 vg/eye) + EYLEA® (aflibercept) Injection 2 mg (0.05mL)Phase 3
69
4D-150 IVT + Aflibercept IVTPhase 2
44
4D-710Phase 2
44
4D-150 IVT + Aflibercept IVTPhase 1/2
33